Published in Blood on December 15, 1997
Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 22.23
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A (2002) 2.19
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med (2009) 2.17
Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One (2008) 2.10
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med (2000) 1.89
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene (2010) 1.63
Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J Cancer Res Clin Oncol (2007) 1.59
Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther (2010) 1.59
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol (2008) 1.44
Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J (2000) 1.44
A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. J Exp Med (2015) 1.42
Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol (2009) 1.40
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. Proc Natl Acad Sci U S A (1998) 1.25
Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol (2011) 1.25
Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest (2007) 1.22
A role for PDGF signaling in expansion of the extra-embryonic endoderm lineage of the mouse blastocyst. Development (2010) 1.18
Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. Am J Pathol (2002) 1.15
67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest (2013) 1.14
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res (2009) 1.14
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood (2009) 1.13
Spontaneous rupture of giant gastric stromal tumor into gastric lumen. World J Surg Oncol (2005) 1.13
STAT signaling in the pathogenesis and treatment of cancer. Mol Med (1999) 1.11
Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe (2011) 1.10
Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis Tissue Repair (2011) 1.05
TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol Cell Proteomics (2012) 1.04
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol (2004) 1.02
Association of platelet-derived growth factor-B chain with simian human immunodeficiency virus encephalitis. Am J Pathol (2004) 1.00
Effects of STI571 (gleevec) on pancreatic cancer cell growth. Mol Cancer (2003) 0.98
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood (2008) 0.98
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol Cell Biol (2014) 0.92
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag (2008) 0.90
Lung involvement in systemic sclerosis. Presse Med (2010) 0.90
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest (2004) 0.90
PDGF signaling is required for primitive endoderm cell survival in the inner cell mass of the mouse blastocyst. Stem Cells (2013) 0.90
Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clin Exp Immunol (2006) 0.89
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther (2014) 0.87
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer (2004) 0.87
Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat. Am J Physiol Heart Circ Physiol (2013) 0.86
Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int (2006) 0.85
The legacy of the Philadelphia chromosome. J Clin Invest (2007) 0.85
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors. Leuk Lymphoma (2009) 0.84
Attacking cancer at its foundation. Nat Med (2009) 0.83
The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β (Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp). J Biol Chem (2012) 0.82
A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. Gastrointest Cancer Res (2012) 0.82
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias. PLoS One (2014) 0.81
Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Respir Med (2009) 0.81
Abelson tyrosine kinase links PDGFbeta receptor activation to cytoskeletal regulation of NMDA receptors in CA1 hippocampal neurons. Mol Brain (2008) 0.81
Characterization of leukemias with ETV6-ABL1 fusion. Haematologica (2016) 0.80
Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog (2015) 0.80
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr (2003) 0.79
Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis (2014) 0.79
Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma. BMC Cancer (2012) 0.77
Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res (2011) 0.77
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. BMC Pharmacol (2007) 0.77
STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia (2013) 0.76
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity. Int J Nanomedicine (2015) 0.76
Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases. Drug Target Insights (2007) 0.75
Short-term vasculoprotective effects of imatinib mesylate on intimal hyperplasia of arterial anastomosis: An experimental study using a rabbit model. Can J Plast Surg (2012) 0.75
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Ann Gastroenterol (2016) 0.75
Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents. ISRN Oncol (2012) 0.75
Preclinical approaches in CML: From cells to systems. Exp Hematol (2016) 0.75
Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors. Oncotarget (2016) 0.75
Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells. PLoS One (2014) 0.75
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol (2016) 0.75
An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL. Leuk Res Rep (2016) 0.75
Chordoma: The Quest for Better Treatment Options. Oncol Ther (2016) 0.75
Medulloblastoma: Molecular Classification-Based Personal Therapeutics. Neurotherapeutics (2017) 0.75
Effects of STI571 and p27 gene clone on proliferation and apoptosis of K562 cells. World J Gastroenterol (2005) 0.75
BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. Cell Death Dis (2017) 0.75
Promising approaches in acute leukemia. Invest New Drugs (2000) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Automated DNA sequencing of the human HPRT locus. Genomics (1990) 5.92
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 5.09
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 4.64
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med (1994) 4.46
Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc (1996) 4.33
Presence of an SH2 domain in the actin-binding protein tensin. Science (1991) 4.03
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
Complete DNA sequence of yeast chromosome XI. Nature (1994) 3.51
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1995) 3.38
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood (2000) 3.26
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat Genet (2001) 2.85
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst (1999) 2.81
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res (2001) 2.79
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood (1996) 2.73
Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol (1991) 2.71
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest (1993) 2.64
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res (2000) 2.43
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
New retraction technique to allow better visualization of Calot's triangle during laparoscopic cholecystectomy. Surg Endosc (1998) 2.35
STI571: targeting BCR-ABL as therapy for CML. Oncologist (2001) 2.15
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J (1997) 2.06
Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells (2000) 2.05
Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut (2005) 2.03
Simultaneous on-line DNA sequencing on both strands with two fluorescent dyes. Anal Biochem (1995) 2.01
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med (1998) 2.01
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A (1996) 1.98
Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension (1998) 1.96
E-cadherin mediated adhesion system in cancer cells. Cancer (1996) 1.94
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Retracted Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A (1995) 1.93
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res (2000) 1.88
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem (1995) 1.81
A new technique for laparoscopic resection of a submucosal tumor on the posterior wall of the gastric fundus. Surg Endosc (1999) 1.80
A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. J Biol Chem (1984) 1.79
Chronic myelogenous leukemia. Curr Opin Oncol (2001) 1.78
Endoscopic diagnosis and treatment of early colorectal cancer. World J Surg (1997) 1.77
Human PEX19: cDNA cloning by functional complementation, mutation analysis in a patient with Zellweger syndrome, and potential role in peroxisomal membrane assembly. Proc Natl Acad Sci U S A (1999) 1.75
The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol (1996) 1.75
Structure of rhodotorucine A, a novel lipopeptide, inducing mating tube formation in Rhodosporidium toruloides. Biochem Biophys Res Commun (1978) 1.74
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine (2000) 1.63
Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods (1997) 1.62
Chronic myeloid leukemia: current treatment options. Blood (2001) 1.62
Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine (1990) 1.62
E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res (1994) 1.61
Endoscopic screening of early esophageal cancer with the Lugol dye method in patients with head and neck cancers. Cancer (1990) 1.58
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol (2005) 1.56
The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev (1998) 1.55
Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood (1998) 1.55
Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc Natl Acad Sci U S A (1994) 1.55
Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci U S A (1980) 1.54
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res (2001) 1.53
Protein tyrosine kinases and cancer. Biochim Biophys Acta (1997) 1.52
Hematologic malignancies. Curr Opin Hematol (2001) 1.52
"Giant" colon lipoma: what kind of findings are necessary for the indication of endoscopic resection? Am J Gastroenterol (2001) 1.51
Computerized classification of interstitial lung abnormalities on chest radiographs with normalized radiographic index and normalized fractal dimension. Eur J Radiol (2001) 1.51
Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res (2001) 1.50
The problem of de novo colorectal carcinoma. Eur J Cancer (1995) 1.49
Beta-catenin expression in human cancers. Am J Pathol (1996) 1.47
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer (2001) 1.47
Local field enhancement effects for nanostructuring of surfaces. J Microsc (2001) 1.45
Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol (1972) 1.44
Regulation of the TAK1 signaling pathway by protein phosphatase 2C. J Biol Chem (2000) 1.44
Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J (2000) 1.44
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem (1994) 1.43
The peroxin Pex14p. cDNA cloning by functional complementation on a Chinese hamster ovary cell mutant, characterization, and functional analysis. J Biol Chem (1999) 1.41
High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology (1996) 1.41
Hemodynamic responses to noxious stimuli in brain-dead organ donors. Intensive Care Med (1992) 1.41
Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol (2001) 1.41
Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch (1994) 1.40
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res (2000) 1.39